Clinical Trials Logo

Clinical Trial Summary

One of the risks associated with heart transplantation is failure of the graft. A graft is where the new heart is attached to the original vessels in the body. Approximately 10% of children suffer graft failure which, leads to heart failure and possible death. The problem is that we do not know some of the causes of graft failure thus, it is difficult to diagnose early and treat. Due to graft failure, lots of children are placed back on the transplant list and receive another new heart.

In this study, we plan to perform a retrospective chart review looking to see if we can correlate graft failure with a problem with the vessels called coronary allograft vasculopathy or rejection. In order to do this, we will collect data from patient's charts that have been diagnosed with graft failure and compare their clinical presentation/data to pathology reports of the explanted hearts from these children. Explanted hearts are the old transplanted hearts that are removed in order to put a new heart into the body. Explanted hearts at our institution are always sent to pathology for analysis thus it will be quite easy to perform this review.


Clinical Trial Description

The objectives are to describe the pathology findings from the examination of the explanted heart and correlate them with clinical variables such as catheterization data.

Children's Healthcare of Atlanta performs approximately 12-15 heart transplants a year. To date, there have been 19 re-transplantations for late graft failure at Children's. The pathologic and clinical records of these 19 patients will be studied. All data collected will be entered into a database for future analysis.

Data Collection

A retrospective review of standard pathology findings from the examination of the explanted hearts will be conducted in order to determine the following:

1. Evidence of CAV (coronary allograft vasculopathy)

2. Evidence of Endocardial fibroelastosis

3. Evidence of Rejection (acute and chronic)

4. Evidence of Myocardial infarction

5. Evidence of Fibrosis

6. Evidence of Fatty infiltration

A retrospective review of patient charts will also be utilized to compare the pathologic findings to clinical data obtained prior to re-transplantation. The following information will be collected:

1. Type of transplant method

2. Patient age at time of transplant

3. Echocardiographic Data including Tissue Doppler Imaging (if available)

4. Catheterization data

1. CAV as identified by coronary angiography

2. Ventricular end-diastolic pressure

3. Cardiac index

4. Ventricular ejection fraction

5. Clinical rejection history ;


Study Design

Time Perspective: Retrospective


Related Conditions & MeSH terms


NCT number NCT00208884
Study type Observational
Source Emory University
Contact
Status Terminated
Phase N/A
Start date October 2003
Completion date November 2005

See also
  Status Clinical Trial Phase
Recruiting NCT03948529 - RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation Phase 2
Completed NCT03663036 - Arthroscopic Superior Capsular Reconstruction With Fascia Lata Autograft - Survivorship of the Autograft Analysis N/A
Not yet recruiting NCT05855707 - Wharton Jelly Mesenchymal Stromal Cells as GVHD Prophylaxis Phase 1
Recruiting NCT04967391 - Tumescence in HNC Skin Graft Reconstruction Phase 3
Recruiting NCT02061462 - EVLP to Evaluate the Eligibility for Transplantation of DCD-Lungs Phase 1
Completed NCT01970605 - Silver Graft All Comers Registry
Terminated NCT01564095 - TOP-Study (Tacrolimus Organ Perfusion): Treatment of Ischemia Reperfusion Injury in Marginal Organs With an ex Vivo Tacrolimus Perfusion Phase 2/Phase 3
Recruiting NCT04779957 - Evaluation of the Safety of Use of Anti-IL6 Receptor Antibodies to Reduce Allo-sensitization Post Allograft Nephrectomy Phase 2
Terminated NCT04494061 - A Clinical Study to Investigate Interferon Gamma (IFNɣ) Signature in Patients Post HSCT and in Patients With Impaired HSC Proliferation Pre-transplant
Terminated NCT04731298 - Study to Investigate the Pharmacokinetics, Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After HSCT. Phase 2
Completed NCT01848249 - Deceased Donor Biomarkers and Recipient Outcomes
Active, not recruiting NCT02556879 - Immunization Anti HLA in the Liver Transplant Recipients (DSATH) N/A
No longer available NCT02026934 - CliniMACS® CD34+ Reagent System for Expanded Access Use N/A
Recruiting NCT00472329 - Fludarabine and 400 CGY Total Body Irradiation for Recipients of HLA-Matched or Mis-Matched Family or Unrelated Donor Hematopoietic Stem Cell Transplants Who Have Rejected Their First Allogeneic Stem Cell Transplant Phase 2
Completed NCT04542954 - Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience From the Middle East
Recruiting NCT03717545 - Second Transplantation for Graft Failure N/A
Recruiting NCT03019809 - A Trial of Plerixafor/G-CSF as Additional Agents for Conditioning Before TCR Alpha/Beta Depleted HSCT in WAS Patients Phase 2
Recruiting NCT01631058 - Renal Transplantation in the Elderly - nEverOld Study Phase 4
Completed NCT06340607 - Neohepatic Albumin-Bilirubin Scores on Renal Outcomes in Living-donor Liver Transplantation Recipients
Not yet recruiting NCT04685174 - Intraoperative NIRS of Transplanted Kidney for Prediction of Acute and Sub-acute Injury Phase 3